A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Study of BMS-986177, an Oral Factor Xla Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Asprin and C...